
 Substitute Form PTO-1449  
(Modified)

 U.S. Department of Commerce  
Patent and Trademark Office

 Attorney's Docket No.  
10274-006002

 Application No.  
09/730,465

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

 Applicant  
Wallner et al.

 Filing Date  
December 5, 2000

Group Art Unit

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,336,603	August 9, 1994	Capon et al.			
	AB	5,565,335	October 15, 1996	Capon et al.			
	AC	5,728,677	March 17, 1998	Wallner et al.			
	AD	5,928,643	July 27, 1999	Wallner et al.			
	AE	6,162,432	Dec 19, 2000	Wallner et al.			
	AF	5,547,853	August 20, 1996	Wallner et al.			
	AG	6,117,655	September 12, 2000	Capon et al.			
	AH	5,914,111	June 2, 1999	Wallner et al.			
	AI						
	AJ						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AK							
	AL							
	AM							
	AN							
	AO							
	AP							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	AQ	Actis, et al., "Continuously Infused Cyclosporine at Low Dose Is Sufficient to Avoid Emergency Colectomy in Acute Attacks of Ulcerative Colitis Without the Need for High-Dose Steroids", <i>Journal of Clinical Gastroenterology</i> , Vol. 17, No. 1, pp. 10-13, 1993.
	AR	Adams, "How the Immune System Works and Why it Causes Autoimmune Diseases" <i>Immunology Today</i> , 1996 Jul;17(7):300-2

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified) JUL 8 7 2003 (37 CFR 1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
<b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)		Applicant Wallner et al.	
		Filing Date December 5, 2000	Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	AS	Alcover, et al., "Interdependence of CD3-Ti and CD2 Activation Pathways in Human T Lymphocytes", <i>The EMBO Journal</i> , Vol. 7, No. 7, pp. 1973-1977, 1988.
	AT	Alora, and Taylor, "Narrow-band (311 nm) UVB Phototherapy: An Audit of the First Year's experience at the Massachusetts General Hospital", <i>Photodermatology Photoimmunology &amp; Photomedicine</i> , Vol. 13, pp. 82-84, 1997.
	AU	Altmeyer, and Nuchel, "Traitement Systemique Du Psoriasis Par Les Derives De L'Acide Fumarique", <i>Ann. Dermatol. Venerol.</i> , Vol. 123, pp. 838-841, 1996.
	AV	Altschuler, "Implications of Psoriasis as a New Disease", <i>Dermatology</i> , Vol. 199, pp. 1-2, 1999.
	AW	Arbuckle, and Hartley, "Psoriasis" <i>Pediatrics in Review</i> , 1998 Mar;19(3):106-7.
	AX	Arellano, "Risk of Cancer with Cyclosporine in Psoriasis" <i>International Journal of Dermatology</i> , Vol. 36, No. 1, pp. 15-17, 1997.
	AY	Arend, "The Pathophysiology and Treatment of Rheumatoid Arthritis" <i>Arthritis &amp; Rheumatism</i> , Vol. 40, No. 4, pp. 595-597, 1997.
	AZ	Armitage, "Tests for Linear Trends in Proportions and Frequencies" <i>Biometrics</i> , 11, 375-386, 1955
	AAA	Asadullah, et al., "IL-10 Is a Key Cytokine in Psoriasis", <i>Journal of Clinical Investigation</i> , Vol. 101, No. 4, pp. 783-794, 1998.
	ABB	Ashcroft, et al., "Clinical Measures of Disease Severity and Outcome in Psoriasis: A Critical Appraisal of their Quality" <i>British Journal of Dermatology</i> , Vol. 141, pp. 185-191, 1999.
	ACC	Bangha, and Elsner, "Evaluation of Topical Antipsoriatic Treatment by Chromametry, Visiometry and 20-MHz Ultrasound in the Psoriasis Plaque Test", <i>Skin Pharmacology</i> , Vol. 9, pp. 298-306, 1996.
	ADD	Bansil, et al., "Multiple Sclerosis: Immune Mechanism and Update on Current Therapies" <i>Annals of Neurology</i> , Vol. 37, pp. 87-101, 1995.
	AEE	Bardolph, and Ashton, "Psoriasis: A Review of Present and Future Manangement", <i>Nursing Standard</i> , Vol. 12, No. 21, pp. 43-47, 1998.
	AFF	Barker, "The Pathophysiology of Psoriasis", <i>The Lancet</i> , Vol. 338, pp. 227-230, 1991.
	AGG	Barker, and Nickoloff, "Leukocyte-Endothelium Interactions in Cutaneous Inflammatory Processes", <i>Springer Seminars in Immunopathology</i> , Vol. 13, pp. 355-367, 1992.
	AHH	Barker, et al., "Topical Maxacalcitol for the Treatment of Psoriasis Vulgaris: A Placebo-Controlled, Double-Blind, Dose-Finding Study with Active Comparator", <i>British Journal of Dermatology</i> , Vol. 141, pp. 274-278, 1999.
	AII	Barker, "Psoriasis" <i>Journal of the Royal College of Physicians of London</i> , Vol. 31, No. 3, pp. 238-240, 1997.
	AJJ	Barsoum, "Introduction of Stable High-Copy-Number DNA into Chinese Hamster Ovary Cells by Electroporation" <i>DNA and Cell Biology</i> , Vol. 9, No. 4, pp. 293-300, 1990.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.

10274-006002

Application No.

09/730,465

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant

Wallner et al.

Filing Date

December 5, 2000

Group Art Unit

(37 CFR 1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	AKK	Bay, et al., "Psoriasis Patients have T-cells with Reduced Responsiveness to Common Mycobacterial Antigens", <i>FEMS Immunology and Medical Microbiology</i> , Vol. 21, pp. 65-70, 1998.
	ALL	Bell, and Imboden, "CD2 and the Regulation of T Cell Anergy", <i>J. Immunol.</i> 1995 Sep 15;155(6):2805-7.
	AMM	Bennett, "Cyclosporine Nephrotoxicity: Implications for Dermatology", <i>International Journal of Dermatology</i> , Vol. 36, pp. 11-14, 1997.
	ANN	Berth-Jones, et al., "Treatment of Psoriasis with Intermittent Short Course Cyclosporin (Neoral®). A Multicentre Study", <i>British Journal of Dermatology</i> , Vol. 136, pp. 527-530, 1997.
	AOO	Bjerke, and Geiger, "Acitretin Versus Etretnate in Severe Psoriasis. A double-blind Randomized Nordic Multicenter Study in 168 Patients", <i>Acta Derm Venereol Suppl (Stockh)</i> , Vol. 146, pp. 206-207, 1989.
	APP	Bjerring, et al., "Topical Treatment of Psoriatic Skin with Methotrexate Cream: A Clinical, Pharmacokinetic, and Histological Study", <i>Acta Derm Venereol (Stockh)</i> , Vol. 66, pp. 515-519, 1986.
	AQQ	Boehncke, et al., "Differential Expression of Adhesion Molecules on Infiltrating Cells in Inflammatory Dermatoses", <i>Journal of American Academy of Dermatology</i> , Vol. 26, No. 6, pp. 907-913, 1992.
	ARR	Bonifati, et al., "Recognition and Treatment of Psoriasis: Special Considerations in Elderly Patients" <i>Drugs &amp; Aging</i> , Vol. 12, No. 3, pp. 177-190, 1998.
	ASS	Borroni, et al., "Evidence for CD8+ Cell Increase in Long-Term PUVA-Treated Psoriatic Patients after PUVA Discontinuation", <i>Dermatology</i> , Vol. 185, pp. 69-71, 1992.
	ATT	Bos, and Ric, "Immunologie in de Medische Praktijk. VII. Psoriasis", <i>Ned Tijdschr Geneesk</i> , Vol. 141, No. 48, pp. 2334-2338, 1997.
	AUU	Bouhnik, et al., "Long-term Follow-up of Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine", <i>The Lancet</i> , Vol. 347, pp. 215-219, 1996.
	AVV	Brotier, et al., "T Cell Activation Via CD2 [T, gp50] Molecules: Accessory Cells are Required to Trigger T Cell Activation via CD2-D66 Plus CD2-9.6/T11 Epitopes", <i>The Journal of Immunology</i> , Vol. 135, pp. 1624-1631, 1985.
	AWW	Buccheri, et al., "Acitretin Therapy is Effective for Psoriasis Associated with Human Immunodeficiency Virus Infection", <i>Archives of Dermatology</i> , Vol. 133, pp. 711-715, 1997.
	AXX	Burden, "Management of Psoriasis in Childhood", <i>Clinical and Experimental Dermatology</i> , Vol. 24, pp. 341-345, 1999.
	YYY	Burns, et al., "Intralesional Cyclosporine for Psoriasis", <i>Archives of Dermatology</i> , Vol. 128, pp. 786-790, 1992.
	AZZ	Camisa, <i>Psoriasis</i> , Blackwell Scientific Publications, 1994, 1 <sup>st</sup> Ed.
	AAAA	Chandraratna, "Tazarotene: The First Receptor-Selective Topical Retinoid for the Treatment of Psoriasis", <i>American Academy of Dermatology</i> , Vol. 37, No. 2, pp. S12-S17, 1997.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Rev. 11-1997)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR 1.98(b))		Applicant Wallner et al.	
		Filing Date December 5, 2000	Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	ABBB	Christiansen, et al., "Etretinate (Tigason®) and Betamethasone Valerate (Celeston Valerate®) in the Treatment of Psoriasis", <i>Dermatologica</i> , Vol. 165, pp. 204-207, 1982.
	ACCC	Christophers, et al., "Cyclosporine in Psoriasis: A Multicenter Dose-Finding Study in Severe Plaque Psoriasis", <i>Therapy, Journal of the American Academy of Dermatology</i> , Vol. 26, No. 1, pp. 876-90, 1992.
	ADDD	Christophers, and Mrowietz, "The Inflammatory Infiltrate in Psoriasis", <i>Clinics in Dermatology</i> , Vol. 13, pp. 131-135, 1995.
	AEEE	Cohen, and Hanauer, "Immunomodulatory Agents and Other Medical Therapies in Inflammatory Bowel Disease" <i>Current Opinion in Gastroenterology</i> , Vol. 11, pp. 321-330, 1995.
	AFFF	Colten, and Krause, "Pulmonary Inflammation-A Balancing Act", <i>N Engl J Med</i> . 1997 Apr 10;336(15):1094-6.
	AGGG	Crispe, and Mehal, "Strange Brew: T Cells in the Liver" <i>Immunology Today</i> , Vol. 17, No. 11, pp. 522-525, 1996.
	AHHH	Cronstein, "The Mechanism of Action of Methotrexate", <i>Rheumatic Disease Clinics of North America</i> , Vol. 23, No. 4, pp. 739-755, 1997.
	AIII	Danielian, et al., "The Tyrosine Kinase Activity of p56 <sup>lck</sup> is Increased in Human T Cells Activated via CD2", <i>European Journal of Immunology</i> , Vol. 21, pp. 1967-1970, 1991.
	AJJJ	Davies, and Morris, "Physiological Parameters in Laboratory Animals and Humans" <i>Pharmaceutical Research</i> , Vol. 10, No. 7, pp. 1093-1095, 1993.
	AKKK	Dawe, et al., "Narrow-Band (TL-01) Ultraviolet B Phototherapy for Chronic Plaque Psoriasis: Three Times of Five Times Weekly Treatment?" <i>British Journal of Dermatology</i> , Vol. 1, No. 38, pp. 833-839, 1998.
	ALLL	Department of Health & Human Services, "International Conference on Harmonisation" <i>Federal Register</i> , Vol. 62, No. 222, pp. 61515-61519, 1997.
	AMMM	Dinowitz, et al., "Recent Studies on Retrovirus-Like Particles in Chinese Hamster Ovary Cells", <i>Developments in Biological Standardizations</i> , Vol. 76, pp. 201-207, 1991.
	ANNN	Drake, et al., "Guidelines of Care for Psoriasis", <i>Journal of American Academy of Dermatology</i> , Vol. 28, No. 4, pp. 632-637, 1993.
	AOOO	Driscoll, et al., "Structure of Domain 1 of Rat T Lymphocyte CD2 Antigen", <i>Nature</i> , Vol. 353, pp. 762-765, 1991.
	APPP	Dustin, and Springer, "T-Cell Receptor Cross-Linking Transiently Stimulates Adhesiveness Through LFA-1" <i>Nature</i> , Vol. 341, pp. 619-624, 1989.
	AQQQ	Dustin, and Springer, "Role of Lymphocyte Adhesion Receptors in Transient Interaction and Cell Locomotion" <i>Annual Review of Immunology</i> , Vol. 27, pp. 27-66, 1991.


Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Pre-filled)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR § 1.98(b))		Applicant Wallner et al.	
		Filing Date December 5, 2000	Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	ARRR	Dustin, et al., "Low Affinity Interaction of Human or Rat T Cell Adhesion Molecule CD2 with Its Ligand Aligns Adhering Membranes to Achieve High Physiological Affinity", <i>The Journal of Biological Chemistry</i> Vol. 272, No. 49, pp. 30889-30898, 1997.
	ASSS	Dustin, et al., "Correlation of CD2 Binding and Functional Properties of Multimeric and Monomeric Lymphocyte Function-Associated Antigen 3" <i>Journal of Experimental Medicine</i> , Vol. 169, pp. 503-517, 1989.
	ATTT	Dustin, et al., "Anchoring Mechanisms for LFA-3 Cell Adhesion Glycoprotein at Membrane Surface", <i>Nature</i> , Vol. 329, 846-848, 1987.
	AUUU	Duvic, et al., "Molecular Mechanisms of Tazarotene Action in Psoriasis", <i>Journal of American Academy of Dermatology</i> , Vol. 37, No. 2, pp. S18-S24, 1997.
	AVVV	Economidou, et al., "Effects of Cyclosporin A on Immune Activation Markers in Patients with Active Psoriasis", <i>Dermatology</i> , Vol. 199, pp. 144-148, 1999.
	AWWW	Edelhoch, "Spectroscopic Determination of Tryptophan and Tyrosine in Proteins" <i>Biochemistry</i> , Vol. 6, No. 7, pp. 1948-1954, 1967.
	AXXX	Ehmann, and Voorhees, "Effect of Oral Synthetic Retinoids on Keratinizing Disorders", <i>Journal of American Academy of Dermatology</i> , Vol. 6, No. 4, pp. 692-696, 1982.
	YYYY	Ekbom, et al., "Crohn's Disease After In-Utero Measles Virus Exposure", <i>The Lancet</i> , Vol. 348, pp. 515-517, 1996.
	AZZZ	Elder, et al., "Efficacy and Pharmacokinetics of Two Formulations of Cyclosporine A in Patients with Psoriasis" <i>Journal of Clinical Pharmacology</i> , Vol. 35, pp. 865-875, 1995.
	AAAAA	Ellis, et al., "Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial", <i>The New England Journal of Medicine</i> Vol. 324, No. 5, pp. 276-284, 1991.
	ABBBB	Ewe, et al., "Azathioprine and Prednisolone for Active Crohn Disease", <i>ACP Journal Club</i> , 1994, <i>Annals of Internal Medicine</i> 120/2 SUPPL. 1 (13)
	ACCCC	Farber, "Juvenile Psoriasis: Early Interventions Can Reduce Risks for Problems Later" <i>Postgraduate Medicine</i> Vol. 103, No. 4, pp. 89-100, 1998.
	ADDDD	Farber, et al., "Psoriasis: A Disease of the Total Skin" <i>Journal of American Academy of Dermatology</i> , Vol. 12, pp. 150-156, 1985.
	AEEEE	Faulds, et al., "Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders", <i>Drugs</i> , Vol. 45, No. 6, pp. 953-1040, 1993.
	AFFFF	Feagan, et al., "Methotrexate for the Treatment of Crohn's Disease" <i>The New England Journal of Medicine</i> , Vol. 332, pp. 292-297, 1995.
	AGGGG	Feagan, et al., "Therapeutics and Inflammatory Bowel Disease: A Guide to the Interpretation of Randomized Controlled Trials" <i>Gastroenterology</i> , Vol. 110, pp. 275-283, 1996.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


 Substitute Form PTO-1449  
 (Modified)

 U.S. Department of Commerce  
 Patent and Trademark Office

 Attorney's Docket No.  
 10274-006002

 Application No.  
 09/730,465

**Information Disclosure Statement  
 by Applicant**

(Use several sheets if necessary)

 Applicant  
 Wallner et al.

 Filing Date  
 December 5, 2000

Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	AHHHH	Feagan, et al., "Methotrexate Improved Symptoms in Chronic Active Crohn Disease", <i>ACP Journal Club</i> , 1995, Jul-Aug; 123(1) 9
	AIIII	Feldman, et al., "The Economic Impact of Psoriasis Increases with Psoriasis Severity" <i>Journal of American Academy of Dermatology</i> , Vol. 37, pp. 564-569, 1997.
	AJJJJ	Feldman, et al., "The Self-Administered Psoriasis Area and Severity Index Is Valid and Reliable", <i>Journal of Investigative Dermatology</i> , Vol. 106, pp. 183-186, 1996.
	AKKKK	French-Constant, "Pathogenesis of Multiple Sclerosis", <i>The Lancet</i> , Vol. 343, pp. 272-278, 1994.
	ALLLL	Finlay, and Khan, "Dermatology Life Quality Index (DLQI): A Simple Practical Measure for Routine Clinical Use", <i>Clinical and Experimental Dermatology</i> , Vol. 19, pp. 210-216, 1993.
	AMMMM	Finzi, et al., "A Clinical Survey of Psoriasis in Italy: 1 <sup>st</sup> AISP Report" <i>Journal of the European Academy of Dermatology and Venereology</i> , Vol. 10, pp. 125-129, 1998
	ANNNN	Finzi, et al., "Cyclosporin versus Etretnate: Italian Multicenter Comparative Trial in Severe Plaque-Form Psoriasis", <i>Dermatology</i> , Vol. 187, pp. 8-18, 1993.
	AOOOO	Fleischer, Jr., et al., "Patient Measurement of Psoriasis Disease Severity with a Structured Instrument" <i>Journal of Investigative Dermatology</i> , Vol. 102, No. 6, pp. 967-969, 1994.
	APPPP	Fleischer, Jr., et al., "Disease Severity Measures in a Population of Psoriasis Patients: The Symptoms of Psoriasis Correlate with Self-Administered Psoriasis Area Severity Index Scores", <i>Journal of Investigative Dermatology</i> , Vol. 107, No. 1, pp. 26-29, 1996.
	AQQQQ	Fortune, et al., "Quality of Life in Patient with Psoriasis: the Contribution of Clinical Variables and Psoriasis-Specific Stress", <i>British Journal Of Dermatology</i> , Vol. 137, pp. 755-760, 1997.
	ARRRR	Fox, "The Role of T Cells in the Immunopathogenesis of Rheumatoid Arthritis", <i>Arthritis &amp; Rheumatism</i> , Vol. 40, No. 4, pp. 598-609, 1997.
	ASSSS	Georgouras, et al., "Systemic Treatment of Severe Psoriasis", <i>Australasian Journal of Dermatology</i> , Vol. 38, pp. 171-182, 1997.
	ATTTT	Gismondi, et al., "Triggering through CD16 or Phorbol Esters Enhances Adhesion of NK Cells to Laminin via Very Late Antigen 6", <i>Journal of Experimental Medicine</i> , Vol. 176, pp. 1251-1257, 1992.
	AUUUU	Goebell, et al., "Drug Trials in Inflammatory Bowel Diseases 1993-1995: A Survey Conducted by the IOIBD", <i>Inflammatory Bowel Diseases</i> , Vol. 2, pp. 265-267, 1996.
	AVVVV	Goldman, et al., "OKT3-Induced Cytokine Release Attenuation by High-Dose Methylprednisolone", <i>Lancet</i> . 1989 Sep 30;2(8666):802-3.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449  
 (Modified)

 U.S. Department of Commerce  
 Patent and Trademark Office

 Attorney's Docket No.  
 10274-006002

 Application No.  
 09/730,465

**Information Disclosure Statement**
**by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

 Applicant  
 Wallner et al.

 Filing Date  
 December 5, 2000

Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	AWWWWW	Gollnick, et al., "Acitretin" versus Etretinate in Psoriasis: Clinical and Pharmacokinetic Results of a German Multicenter Study", <i>Journal of American Academy of Dermatology</i> , Vol. 19, No. 3, pp. 458-468, 1988.
	AXXXX	Gollob, et al., "CD2 Regulates Responsiveness of Activated T Cells to Interleukin 12", <i>Journal of Experimental Medicine</i> , Vol. 182, pp. 721-731, 1995.
	AYYYY	Gottlieb, "The Challenges of Treating Moderate to Severe Psoriasis", <i>International Journal of Dermatology</i> , Vol. 36, pp. 41-44, 1997.
	AZZZZ	Greaves, and Weinstein, "Treatment of Psoriasis", <i>The New England Journal of Medicine</i> , Vol. 332, No. 9, pp. 581-588, 1995.
	AAAAAA	Greenberg, et al., "Oral Budesonide for Active Crohn's Disease", <i>The New England Journal of Medicine</i> , Vol. 331, No. 13, pp. 836-845, 1994.
	ABBBBB	Grossman, et al., "Long-term Safety of Cyclosporine in the Treatment of Psoriasis", <i>Archives of Dermatology</i> , Vol. 132, pp. 623-629, 1996.
	ACCCCC	Grossman, et al., "A Novel Therapeutic Approach to Psoriasis with Combination Calcipotriol Ointment and Very-Low-Dose Cyclosporine: Results of a Multicenter Placebo-Controlled Study", <i>Journal of American Academy of Dermatology</i> , Vol. 31, No. 1, pp. 68-74, 1994.
	ADDDDD	Guckian, et al., "Immunomodulation at the Initiation of Phototherapy and photochemotherapy", <i>Photodermatology, Photoimmunology &amp; Photomedicine</i> , Vol. 11, pp. 163-169, 1995.
	AEEEEEE	Gulliver, et al., Increased Bioavailability and Improved Efficacy, in Severe Psoriasis, of a New Microemulsion Formulation of Cyclosporin*", <i>British Journal Of Dermatology</i> , Vol. 135, pp. 35-39, 1996.
	AFFFFFF	Guzzo, "Recent Advances in the Treatment of Psoriasis", <i>Dermatologic Clinics</i> , Vol. 15, No. 1, pp. 59-68, 1997.
	AGGGGG	Hamblin, "From Dendritic Cells to Tumour Vaccines", Vol. 347, pp. 705-706, 1996.
	AHHHHH	Hanauer, "Inflammatory Bowel Disease", <i>Drug Therapy</i> , Vol. 334, No. 13, pp. 841-848, 1996.
	AIIIII	Hanauer, "Medical Therapy of Ulcerative Colitis" <i>The Lancet</i> , Vol. 342, pp. 412-417, 1993.
	AJJJJJ	Hardman, et al., "Active Psoriasis and Profound CD4 <sup>+</sup> Lymphocytopenia", <i>British Journal Of Dermatology</i> , Vol. 136, pp. 930-932, 1997.
	AKKKKK	Hawke, et al., "Autoimmune T Cells in Myasthenia Gravis: Heterogeneity and Potential for Specific Immunotargeting", <i>Immunology Today</i> , Vol. 17, No. 7, pp. 307-311, 1996.
	ALLLLL	Henseler, "The Genetics of Psoriasis", <i>Journal of American Academy of Dermatology</i> , Vol. 37, No. 2, pp. S1-S11, 1997.
	AMMMMM	Henseler, and Christophers, "Disease Concomitance in Psoriasis", <i>Journal of American Academy of Dermatology</i> , Vol. 32, pp. 982-986, 1997.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
10274-006002Application No.  
09/730,465**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant  
Wallner et al.Filing Date  
December 5, 2000

Group Art Unit

(37 CFR 1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	ANNNNN	Henseler, and Christophers, "Psoriasis of Early and Late Onset: Characterization of Two Types of Psoriasis Vulgaris", <i>Journal of American Academy of Dermatology</i> , Vol. 13, no. 3, pp. 450-456, 1995.
	AOOOOO	Herbin, et al., "Automated Registration of Dissimilar Images: Application to Medical Imagery", <i>Computer Vision, Graphics, and Image Processing</i> , Vol. 47, pp. 77-88, 1989.
	APPPPP	Hiramine, et al., "Differential Effect of Cyclosporine in Vivo on the Distribution of T cell Subsets in the Thymus, Spleen, and Lymph Nodes", <i>Transplantation</i> , Vol. 47, No. 3, pp. 499-503, 1989.
	AQQQQQ	Hirano, et al., "Individual Pharmacodynamics Assessed by Antilymphocyte Action Predicts Clinical Cyclosporine Efficacy in Psoriasis", <i>Clinical Pharmacology &amp; Therapeutics</i> , Vol. 63, No. 4, pp. 465-470, 1998.
	ARRRRR	Ho, et al., "Intermittent Short Courses of Cyclosporin (Neoral®) for Psoriasis Unresponsive to Topical Therapy: A 1-Year Multicentre, Randomized Study", <i>British Journal Of Dermatology</i> , Vol. 141, pp. 283-291, 1999.
	ASSSSS	Honeyman, et al., "Low-Dose Cyclosporine a Improves Severe Disabling Psoriasis in Latin America", <i>International Journal of Dermatology</i> , Vol. 34, pp. 583-588, 1995.
	ATTTTT	Hopkins, et al., "A double-Blind Controlled Trial of Etretinate (Tigason) and Ibuprofen in Psoriatic Arthritis", <i>Annals of the Rheumatic Diseases</i> , Vol. 44, pp. 189-193, 1985.
	AUUUUU	Hugot, et al., "Mapping of a Susceptibility Locus for Crohn's Disease on Chromosome 16", <i>Nature</i> , Vol. 379, pp. 821-823, 1996.
	AVVVVV	Hunt, et al., "Generalized Pustular Psoriasis Responsive to PUVA and Oral Cyclosporin Therapy", <i>Australasian Journal of Dermatology</i> , Vol. 38, pp. 199-201, 1997.
	AWWWWW	Ieiri, et al., "Evaluation of the Therapeutic Range of Whole Blood Cyclosporin Concentration in the Treatment of Psoriasis", <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 34, No. 3, pp. 106-111, 1996.
	AXXXXX	Ikemizu, et al., "Crystal Structure of the CD2-Binding Domain of CD58 (Lymphocyte Function-Associated Antigen 3) at 1.8-Å Resolution", <i>Proceedings of the National Academy of Science</i> , Vol. 96, pp. 4289-4294, 1999.
	AYYYYY	Ip, et al., Structural Characterization of the N-Glycans of a Humanized Anti-CD18 Murine Immunoglobulin G", <i>Archives of Biochemistry and Biophysics</i> , Vol. 308, No. 2, pp. 387-399, 1994.
	AZZZZZ	Isaacs, et al., "Humanized Anti-CD4 Monoclonal Antibody Therapy of Autoimmune and Inflammatory Disease", <i>Clinical and Experimental Immunology</i> , Vol. 110, pp. 158-166, 1997.
	AAAAAAA	Jefferis, and Lund, "Glycosylation of Antibody Molecules: Structural and Functional Significance", <i>Chemical Immunology</i> , Vol. 65, pp 111-113, 1997.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)




	Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 10274-006002	Application No. 09/730,465
	<b>Information Disclosure Statement</b> by Applicant (Use several sheets if necessary)					
	Applicant Wallner et al.					Filing Date December 5, 2000
						Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	ABBBBBB	Jemec, and Wulf, "The Applicability of Clinical Scoring Systems: SCORAD and PASI in Psoriasis and Atopic Dermatitis", <i>Acta Derm Venereol (Stockholm)</i> , Vol. 77, pp. 392-393, 1997.
	ACCCCCC	Jenkins, et al., "CD28 Delivers A Constitutively Stimulatory Signal Involved in Antigen-Specific IL-2 Production by Human T Cells", <i>The Journal of Immunology</i> , Vol. 147, pp. 2461-2466, 1991.
	ADDDDDD	Johnson, "On Teaching Dermatology to Nondermatologists", <i>Arch Dermatol</i> , Vol. 130, pp. 850-852, 1994.
	AEEEEEE	Jones, et al., "Crystal Structure at 2.8 Å Resolution of a Soluble Form of the Cell Adhesion Molecule CD2", <i>Nature</i> , Vol. 360, pp. 232-239, 1992.
	AFFFFFF	June, "Increases in Tyrosine Phosphorylation are Detectable Before Phospholipase C Activation After T Cell Receptor Stimulation", <i>The Journal of Immunology</i> , Vol. 144, No. 5, pp. 1591-1599, 1990.
	AGGGGGG	Kang, et al., "Calcipotriene-Induced Improvement in Psoriasis is Associated with Reduced Interleukin-8 and Increased Interleukin-10 levels within Lesions", <i>British Journal of Dermatology</i> , Vol. 138, pp. 77-83, 1998.
	AHHHHHH	Kanner, et al., "CD2/LFA-3 Ligation Induces Phospholipase-C $\gamma$ 1 Tyrosine Phosphorylation and Regulates CD3 Signaling", <i>The Journal of Immunology</i> , Vol. 148, No. 7, pp. 2023-2029, 1992.
	AIIIIII	Kantor, et al., "Double-Blind Bilateral Paired Comparison of 0.05% Halobetasol Propionate Cream and its Vehicle in Patients with Chronic Atopic Dermatitis and Other Eczematous Dermatoses", <i>Journal of the American Academy of Dermatology</i> , Vol. 25, No. 6, pp. 1184-1186, 1991.
	AJJJJJJ	Kato, et al., "CD48 is a Counter-Receptor for Mouse CD2 and is Involved in T Cell Activation", <i>Journal of Experimental Medicine</i> , Vol. 176, pp. 1241-1249, 1992.
	AKKKKKK	Kaufman, and Sharp, "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene", <i>Journal of Molecular Biology</i> , Vol. 159, pp. 601-621, 1982.
	ALLLLLL	Kaufman, and Sharp, "Construction of a Modular Dihydrofolate Reductase cDNA Gene: Analysis of Signals Utilized for Efficient Expression", <i>Molecular and Cellular Biology</i> , Vol. 2, No. 11, pp. 1304-1319, 1982.
	AMMMMMM	Kelso, "Th1 and Th2 Subsets: Paradigms Lost?", <i>Immunology Today</i> , Vol. 16, No. 8, pp. 374-379, 1995.
	ANNNNNN	Killeen, et al., "The MRC OX-45 Antigen of Rat Leukocytes and Endothelium is in a Subset of the Immunoglobulin Superfamily with CD2, LFA-3 and Carcinoembryonic Antigens", <i>The EMBO Journal</i> , Vol. 7, No. 10, pp. 3087-3091, 1988.
	AOOOOOO	Kingston, et al., "Etretin Therapy for Severe Psoriasis", <i>Arch Dermatol</i> , Vol. 123, pp. 55-58, 1987.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	




Substitute Form PTO-1449 Modified Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
		Applicant Wallner et al.	
		Filing Date December 5, 2000	Group Art Unit

### Other Documents (include Author, Title, Date, and Place of Publication)

Exam iner Initial	Desig. ID	Document
	APPPPPP	Kollias, "Letter to the Editor: Simple Changes to PUVA Phototherapy May Minimize the Photocarcinogenic Risks", <i>Photodermatology, Photoimmunology, &amp; Photomedicine</i> , Vol. 15, pp. 205, 1999.
	AQQQQQQ	Koo, "Neoral in Psoriasis Therapy: Toward a New Perspective", <i>International Journal of Dermatology</i> , Vol. 36, pp. 25-29, 1997.
	ARRRRRR	Koo, "Systematic Sequential Therapy of Psoriasis: A New Paradigm for Improved Therapeutic Results", <i>Journal of the American Academy of Dermatology</i> , Vol. 41, No. 3, pp. S25-S28, 1999.
	ASSSSSS	Koo, "Population-Based Epidemiological Study of Psoriasis with Emphasis on Quality of Life Assessment", <i>Psychodermatology</i> , Vol. 14, No. 3, pp. 485-496, 1996.
	ATTTTTT	Koo, et al., "Mometasone Furoate 0.1%-Salicylic Acid 5% Ointment Versus Mometasone Furoate 0.1% Ointment in the Treatment of Moderate-to-Severe Psoriasis: A Multicenter Study", <i>Clinical Therapeutics</i> , Vol. 20, No. 2, pp. 283-291, 1998.
	AUUUUUU	Koshy, et al., "Increased Expression of CD40 Ligand on Systemic Lupus Erythematosus Lymphocytes", <i>Journal of Clinical Investigation</i> , Vol. 98, No. 3, pp. 826-837, 1996.
	AVVVVVV	Koyasu, et al., "Role of Interaction of CD2 Molecules with Lymphocyte Function-Associated Antigen 3 in T-Cell Recognition of Nominal Antigen", <i>Proceedings of the National Academy of Science</i> , Vol. 87, pp. 2603-2607, 1990.
	AWWWWWW	Kragballe, et al., "A Double-Blind Comparison of Acitretin and Etrinate in the Treatment of Severe Psoriasis", <i>Acta Derm Venereol (Stockh)</i> , Vol. 69, pp. 35-40, 1989.
	AXXXXXX	Krueger, and Duvic, "Epidemiology of Psoriasis: Clinical Issues", <i>The Journal of Investigative Dermatology</i> , Vol. 102, No. 6, pp. 14S-18S, 1994.
	AYYYYYY	Krueger, et al., "The Safety and Efficacy of Tazarotene Gel, a Topical Acetylenic Retinoid, in the Treatment of Psoriasis", <i>Arch Dermatol</i> , Vol. 134, pp. 57-60, 1998.
	AZZZZZZ	Kullavanijaya, and Kulhanan, "Clinical Efficacy and Side Effects of Acitretin on the Disorders of Keratinization: A One-Year Study", <i>The Journal of Dermatology</i> , Vol. 20, pp. 501-506, 1993.
	AAAAAAA	Kumar, et al., "Short Term Methotrexate Therapy in Psoriasis", <i>Indian J Med Res</i> , Vol. 100, pp. 277-280, 1994.
	ABBBBBBB	Kumar, et al., "Methotrexate in Childhood Psoriasis", <i>Pediatric Dermatology</i> , Vol. 11, No. 3, 271-273, 1994.
	ACCCCCC	Laburte, et al., "Efficacy and Safety of Oral Cyclosporin A (CyA; Sandimmun®) for Long-Term Treatment of Chronic Severe Plaque Psoriasis", <i>British Journal of Dermatology</i> , Vol. 130, pp. 366-375, 1994.
	ADDDDDDD	Lai, et al., "Solid-State Chemical Stability of Proteins and Peptides", <i>Journal of Pharmaceutical Sciences</i> , Vol. 88, No. 5, pp. 489-500, 1999.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

	Substitute Form PTO-1449 Modified	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
	<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant <b>Wallner et al.</b>	
			Filing Date December 5, 2000	Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	AEEEEEEE	Lambert, et al., "Safety and Pharmacokinetics of Hyperimmune Anti-Human Immunodeficiency Virus (HIV) Immunoglobulin Administered to HIV-Infected Pregnant Women and Their Newborns", <i>The Journal of Infectious Diseases</i> , Vol. 175, pp. 283-291, 1997.
	AFFFFFFF	Langford, et al., "Use of Cytotoxic Agents and Cyclosporine in the Treatment of Autoimmune Disease", <i>Annals of Internal Medicine</i> , Vol. 129, No. 1, pp. 49-58, 1998.
	AGGGGGGG	Lanigan, "Treatment of Psoriasis with the Pulsed Dye Laser", <i>Journal of the American Academy of Dermatology</i> , Vol. 37, No. 2, pp. 288-289, 1997.
	AHHHHHHH	Lauharanta, and Geiger, "A Double-Blind Comparison of Acitretin and Eretinate in Combination with Bath PUVA in the Treatment of Extensive Psoriasis", <i>British Journal of Dermatology</i> , Vol. 121, 107-112, 1989.
	AIIIIIII	Lauharanta, et al., "A Clinical Evaluation of the Effects of an Aromatic Retinoid (Tigason), Combination of Retinoid and PUVA, and PUVA Alone in Severe Psoriasis", <i>British Journal of Dermatology</i> , Vol. 104, pp. 325-332, 1981.
	AJJJJJJJ	Lebwohl, et al., "Interactions Between Calcipotriene and Ultraviolet Light", <i>Journal of the American Academy of Dermatology</i> , Vol. 37, No. 1, pp. 93-95, 1997.
	AKKKKKKK	Lebwohl, et al., "Once-Daily Tazarotene Gel Versus Twice-Daily Flucanionide Cream in the Treatment of Plaque Psoriasis", <i>Journal of the American Academy of Dermatology</i> , Vol. 38, No. 5, pp. 705-711, 1998.
	ALLLLLLL	Ledo, et al., "Acitretin (Ro 10-1670) in the Treatment of Severe Psoriasis: A Randomized Double-Blind Parallel Study Comparing Acitretin and Eretinate", <i>International Journal of Psoriasis</i> , Vol. 27, No. 9, pp. 656-659, 1988.
	AMMMMMMM	Lemster, et al., "FK 506 Inhibits Cytokine Gene and Adhesion Molecule Expression in Psoriatic Skin Lesions", <i>Annals of New York Academy of Sciences</i> , Vol. 696, pp. 250-256, 1993.
	ANNNNNNN	Lennard-Jones, "Defining Ulcer Depth in Colitis", <i>The Lancet</i> , Vol. 347, pp. 1708, 1996.
	AOOOOOOO	Letvin, et al., "T Lymphocyte Surface Antigens in Primates", <i>European Journal of Immunology</i> , Vol. 13, pp. 345-347, 1983.
	APPPPPPP	Ley, et al., "The T Cell Receptor/CD3 Complex and CD2 Stimulate the Tyrosine Phosphorylation of Indistinguishable Patterns of Polypeptides in the Human T Leukemic Cell Line Jurkat", <i>European Journal of Immunology</i> , Vol. 21, pp. 2203-2209, 1991.
	AQQQQQQQ	Lichtiger, et al., "Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy", <i>The New England Journal of Medicine</i> , Vol. 330, No. 26, pp. 1841-1845, 1994.
	ARRRRRRR	Lindelof, "Risk of Melanoma with Psoralen/Ultraviolet A Therapy for Psoriasis", <i>Drug Safety</i> , Vol. 20, No. 4, pp. 289-297, 1999.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR § 1.98(b))		Applicant <b>Wallner et al.</b>	
		Filing Date December 5, 2000	Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	ASSSSSSS	Llewellyn-Smith, et al., "Effects of Anti-CD4 Antibody Treatment on Lymphocyte Subsets and Stimulated Tumor Necrosis Factor Alpha Production: A Study of 29 Multiple Sclerosis Patients Entered into a Clinical Trial of cM-T412", <i>Neurology</i> , Vol. 48, pp. 810-816, 1997.
	ATTTTTTT	Lorincz, "Cutaneous T-Cell Lymphoma (Mycosis Fungoides)", <i>The Lancet</i> , Vol. 347, pp. 871-876, 1996.
	AUUUUUUU	Lotti, et al., "Neuropeptides and Skin Disorders. The New Frontiers of Neuro-Endocrine-Cutaneous Immunology", <i>International Journal of Dermatology</i> , Vol. 38, pp. 673-675, 1999.
	AVVVVVVV	Lowe, "Initiating Neoral® Therapy", <i>International Journal of Dermatology</i> , Vol. 36, pp. 30-33, 1997.
	AWWWWWWW	Ludden, "Population Pharmacokinetics", <i>Journal of Clinical Pharmacology</i> , Vol. 28, pp. 1059-1063, 1988.
	AXXXXXXX	Mackay, et al., "Naïve and Memory T Cells Show Distinct Pathways of Lymphocyte Recirculation", <i>J Exp Med.</i> 1990 Mar 1;171(3):801-17.
	AYYYYYYY	Mahrle, et al., "Anti-Inflammatory Efficacy of Low-Dose Cyclosporin A in Psoriatic Arthritis. A Prospective Multicentre Study", <i>British Journal of Dermatology</i> , Vol. 135, pp. 752-757, 1996.
	AZZZZZZZ	Majeau, et al., "Low Affinity Binding of an LFA-3/IgG1 Fusion Protein to CD2+ T Cells is Independent of Cell Activation", <i>Cell Adhesion and Communication</i> , Vol. 7, No. 3, pp. 267-279, 1999.
	AAAAAAAAA	Majewski, et al., "Papillomavirus and Autoimmunity in Psoriasis", <i>Immunology Today</i> , Vol. 20, No. 10, pp. 475-476, 1999.
	ABBBBBBBB	Matsuyama, et al., "The Quantitative and Qualitative Defect of CD4+ CD45RO+ Memory-Type T Cells are Involved in the Abnormality of TH1 Immunity in Atopic Dermatitis Patients", <i>Clinical and Experimental Allergy</i> , Vol. 29, pp. 687-694, 1999.
	ACCCCCCCC	Mazzanti, et al., "Methotrexate and Cyclosporin Combined Therapy in Severe Psoriatic Arthritis. A Pilot Study", <i>Acta Derm Venereol (Stockh)</i> , Suppl. 186, pp. 116-117, 1994.
	ADDDDDDDD	McFarland, "Complexities in the Treatment of Autoimmune Disease", <i>Science</i> , Vol. 274, pp. 2037-2038, 1996.
	AEEEEEEEE	Meffert, and Sonnichsen, "Acitretin in the Treatment of Severe Psoriasis: A Randomized Double-Blind Study Comparing Acitretin and Etretinate", <i>Acta Derm Venereol (Stockh)</i> , Suppl. 146, pp. 176-177, 1989.
	AFFFFFFFF	Meffert, et al., "Low-Dose (1.25 mg/kg) Cyclosporin A: Treatment of Psoriasis and Investigation of the Influence on Lipid Profile", <i>Acta Derm Venereol (Stockh)</i> , Vol. 77, pp. 137-141, 1997.
	AGGGGGGGG	Meingassner, et al., "A Novel Anti-Inflammatory Drug, SDZ ASM 981, for the Topical and Oral Treatment of Skin Diseases: In Vivo Pharmacology", <i>British Journal of Dermatology</i> , Vol. 137, pp. 568-576, 1997.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wallner et al.	
		Filing Date December 5, 2000	Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	AHHHHHHHH	Menter, and Barker, "Psoriasis Practice", <i>The Lancet</i> , Vol. 338, pp. 231-234, 1991.
	AIIIIIIII	Mesalamine Study Group, "An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis: A Randomized Placebo-Controlled Trial", <i>Annals of Internal Medicine</i> , Vol. 124, pp. 204-211, 1996.
	AJJJJJJJ	Mordenti, "Forecasting Cephalosporin and Monobactam Antibiotic Half-Lives in Humans from Data Collected in Laboratory Animals", <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 27, No. 6, pp. 887-891, 1985.
	AKKKKKKKK	Moreland, et al., "Biological Agents for Treating Rheumatoid Arthritis", <i>Arthritis and Rheumatism</i> , Vol. 40, No. 3, pp. 397-409, 1997.
	ALLLLLLLL	Morison, et al., "Consensus Workshop on the Toxic Effects of Long-Term PUVA Therapy" <i>Arch Dermatol</i> , Vol. 134, pp. 595-598, 1998.
	AMMMMMMMM	Mosmann, et al., "The Expanding Universe of T-Cell Subsets: Th1, Th2 and More", <i>Immunology Today</i> , Vol. 17, No. 3, pp. 138-145, 1996.
	ANNNNNNNN	Mrowietz, et al., "Long-Term Maintenance Therapy with Cyclosporine and Posttreatment Survey in Severe Psoriasis: Results of a Multicenter Study", <i>Journal of the American Academy of Dermatology</i> , Vol. 33, No. 3, pp. 470-475, 1995.
	AOOOOOOOO	Murray, et al., "A 12-Month Treatment of Severe Psoriasis with Acitretin: Results of a Canadian Open Multicenter Study", <i>Journal of the American Academy of Dermatology</i> , Vol. 24, No. 4, pp. 598-602, 1991.
	APPPPPPPP	Muchenberger, et al., "The Combination of Oral Acitretin and Bath PUVA for the Treatment of Severe Psoriasis", <i>British Journal of Dermatology</i> , Vol. 137, pp. 587-589, 1997.
	AQQQQQQQQ	Mussi, et al., "Serum TNF-Alpha Levels Correlate with Disease Severity and are Reduced by Effective Therapy in Plaque-Type Psoriasis", <i>J Biol Regul Homeost Agents</i> , Vol. 11, No. 3, pp. 115-118, 1997.
	ARRRRRRRR	Nair, et al., "Evidence for Two Psoriasis Susceptibility Loci (HLA and 17q) and Two Novel Candidate Regions (16q and 20p) by Genome-Wide Scan", <i>Human Molecular Genetics</i> , Vol. 6, No. 8, pp. 1349-1356, 1997.
	ASSSSSSSS	Naldi, et al., "Analytical Epidemiology in Psoriasis", <i>Journal of Investigative Dermatology</i> , Vol. 102, No. 6, pp. 19S-23S, 1994.
	ATTTTTTTT	Nickloff, et al., "Cytokine Networks: Immunobiology Surfaces", <i>The Journal of NIH Research</i> , Vol. 3, pp. 71-74, 1991.
	AUUUUUUUU	Nickloff, "The Cytokine Network in Psoriasis", <i>Arch Dermatol</i> , Vol. 127, pp. 871-884, 1991.
	AVVVVVVVV	Nickloff, et al., "Accessory Cell Function of Keratinocytes for Superantigens: Dependence on Lymphocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction", <i>The Journal of Immunology</i> , Vol. 150, No. 6, pp. 2148-2159, 1993.
	AWWWWWWWW	Nishibu, et al., "Overexpression of Monocyte-Derived Cytokines in Active Psoriasis: A Relation to Coexistent Arthropathy", <i>Journal of Dermatological Science</i> , Vol. 21, pp. 63-70, 1999.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

O JUL 07 2000 PATENT & TRADEMARK OFFICE (37, CFR § 1.98(b))	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
	<b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)		Applicant Wallner et al.	
			Filing Date December 5, 2000	Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AXXXXXXXXX	Olivieri, et al., "Therapy with Cyclosporine in Psoriatic Arthritis", <i>Seminars in Arthritis and Rheumatism</i> , Vol. 27, No. 1, pp. 36-43, 1997.
	AYYYYYYYY	Park, and Youn, "Factors Influencing Psoriasis: An Analysis Based upon the Extent of Involvement and Clinical Type", <i>The Journal of Dermatology</i> , Vol. 25, pp. 97-102, 1998.
	AZZZZZZZZ	Patel, et al., "Compatibility of Calcipotriene with Other Topical Medications", <i>Journal of the American Academy of Dermatology</i> , Vol. 38, No. 6, pp. 1010-1011, 1998.
	AAAAAAAAA	Pavli, et al., "Inflammatory Bowel Disease: Germs or Genes?", <i>The Lancet</i> , Vol. 347, pp. 1198, 1996.
	ABBBBBBBB	Pearson, et al., "Azathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis", <i>Annals of Internal Medicine</i> , Vol. 122, pp. 132-142, 1995.
	ACCCCCCCC	Peckham, et al., "The Treatment of Severe Psoriasis", <i>Arch Dermatol</i> , Vol. 123, pp. 1303-1307, 1987.
	ADDDDDDDD	Peterson, "Genetic Analysis of CD2/LFA-3 and CD4/HIV Interactions," Ph.D. dissertation, Harvard University, July 1988
	AEEEEEEEE	Pettit, "Oral Retinoid for Psoriasis: A Report of a Double Blind Study", <i>Acta Derm Venereol Suppl (Stockh)</i> . 1979;59(85):133-6.
	AFFFFFFFF	Petzeltbauer, et al., "Cyclosporin A Suppresses ICAM-1 Expression by Papillary Endothelium in Healing Psoriatic Plaques", <i>The Journal of Investigative Dermatology</i> , Vol. 96, No. 3, pp. 362-386, 1991.
	AGGGGGGGG	Pitzalis, et al., "Selective Migration of the Human Helper-Inducer Memory T Cell Subset: Confirmation by In Vivo Cellular Studies", <i>European Journal of Immunology</i> , Vol. 21, pp. 369-376, 1991.
	AHHHHHHHH	Podolsky, "Inflammatory Bowel Disease", <i>The New England Journal of Medicine</i> , Vol. 325, No. 13, pp. 928-1014, 1991.
	AIIIIIIII	Poikolainen, et al., "Excess Mortality Related to Alcohol and Smoking Among Hospital-Treated Patients with Psoriasis", <i>Arch Dermatol</i> , Vol. 135, pp. 1490-1493, 1999.
	AJJJJJJJJ	Polito, et al., "Preliminary Evidence for Genetic Anticipation in Crohn's Disease", <i>The Lancet</i> , Vol. 347, pp. 798-800, 1996.
	AKKKKKKKK	Prens, et al., "T Lymphocytes in Psoriasis", <i>Clinics in Dermatology</i> , Vol. 13, pp. 115-129, 1995.
	ALLLLLLLL	Prinz, "Which T Cells Cause Psoriasis?", <i>Clinical and Experimental Dermatology</i> , Vol. 24, pp. 291-295, 1999.
	AMMMMMMMM	Rao, et al., "C-Terminal Modification Occurs in Tissue Culture Produced OKT3", <i>BIOPHARM-THE TECHNOLOGY &amp; BUSINESS OF BIOPHARMACEUTICALS</i> , 1991, V4, N10, P38-43
	ANNNNNNNN	Refsum, et al., "Fasting Plasma Homocysteine as a Sensitive Parameter of Antifolate Effect: A Study of Psoriasis Patients Receiving Low-Dose Methotrexate Treatment", <i>Clinical Pharmacology Therapy</i> , Vol. 46, No. 5, pp. 510-520, 1989.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449

(Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.

10274-006002

Application No.

09/730,465

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant

Wallner et al.

Filing Date

December 5, 2000

Group Art Unit

35 U.S.C. § 1.98(b)

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	A000000000	Reilly, et al., "Problems of Delivery of Monoclonal Antibodies; Pharmaceutical and Pharmacokinetic Solutions", <i>Clinical Pharmacokinetics</i> , Vol. 28, No. 2, pp. 126-142, 1995.
	APPPPPPPPP	Reilly, et al., "Compartmental Analysis of the Pharmacokinetics of Radioiodinated Monoclonal Antibody B72.3 in Colon Cancer Patients", <i>Nucl. Med. Biol.</i> , Vol. 20, No. 1, pp. 57-64, 1993.
	AQ00000000	Rivers, et al., "UVA Sunbeds: Tanning, Photoprotection, Acute Adverse Effects and Immunological Changes", <i>British Journal of Dermatology</i> , Vol. 120, pp. 767-777, 1989.
	ARRRRRRRRR	Rodriguez, et al., "Optic Neuritis Posed a 40-Year Risk of 60% for Multiple Sclerosis", <i>ACP Journal Club</i> , vol. 122-123: 21, 1995.
	ASSSSSSSSS	Salmi, et al., "Dual Binding Capacity of Mucosal Immunoblasts to Mucosal and Synovial Endothelium in Humans: Dissection of the Molecular Mechanisms", <i>Journal of Experimental Medicine</i> , Vol. 181, pp. 137-149, 1995.
	ATTTTTTTTT	Salmi, et al., "Homings of Mucosal Leukocytes to Joints: Distinct Endothelial Ligands in Synovium Mediate Leukocyte-Subtype Specific Adhesion", <i>Journal of Clinical Investigation</i> , Vol. 99, No. 9, pp. 2165-2172, 1997.
	AUUUUUUUUU	Sander, et al., "The Annual Cost of Psoriasis", <i>Journal of the American Academy of Dermatology</i> , Vol. 28, No. 3, pp. 422-425, 1993.
	AVVVVVVVVV	Sanders, et al., "Human Memory T Lymphocytes Express Increased Levels of Three Cell Adhesion Molecules (LFA-3, CD2, and LFA-1) and Three Other Molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN- $\gamma$ Production", <i>The Journal of Immunology</i> , Vol. 140, No. 5, pp. 1401-1407, 1988.
	AWWWWWWWWW	Schraven, et al., "Alterations of CD2 Association with T Cell Receptor Signaling Molecules in 'CD2 Unresponsive' Human T Lymphocytes", <i>European Journal of Immunology</i> , Vol. 23, pp. 119-123, 1993.
	AXXXXXXXXXX	Schwarz, et al., "Identification of the TS2/18-Recognized Epitope on the CD2 Molecule as a Target for Suppression of T Cell Cytokine Synthesis", <i>The Journal of Immunology</i> , Vol. 154, pp. 5813-5820, 1995.
	AYYYYYYYYY	Seed, "An LFA-3 cDNA Encodes a Phospholipid-Linked Membrane Protein Homologous to its Receptor CD2", <i>Nature</i> , Vol. 329, pp. 840-842, 1987.
	AZZZZZZZZZ	Seo, "Evaluation of Disease Activity in Patients with Moderately Active Ulcerative Colitis: Comparisons Between a New Activity Index and Truelove and Witts' Classification", <i>The American Journal Of Gastroenterology</i> , Vol. 90, No. 10, pp. 1759-1763, 1995.
	AAAAAAAAAAAA	Shahidullah, et al., "Etiology Therapy for Psoriasis and Other Keratinizing Disorders: A 10-Year Retrospective Study in Singapore", <i>International Journal of Dermatology</i> , Vol. 32, No. 9, pp. 686-689, 1993.
	ABBBBBBBBBBB	Shanahan, "Pathogenesis of Ulcerative Colitis", <i>The Lancet</i> , Vol. 342, pp. 407-411, 1993.
	ACCCCCCCCC	Shaw, et al., "Cyclosporin A and Vitamin D Metabolism: Studies in Patients with Psoriasis and in Rats", <i>Clinical Science</i> , Vol. 86, pp. 627-632, 1994.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Rev. 10/92)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR § 1.98(b))		Applicant <b>Wallner et al.</b>	
		Filing Date <b>December 5, 2000</b>	Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	ADDDDDDDDD	Shupack, "Maintenance Therapy with Neoral®", <i>International Journal of Dermatology</i> , Vol. 36, pp. 34-36, 1997.
	AEEEEEEEEEE	Singh, et al., "Acute Immobilization Stress Triggers Skin Last Cell Degranulation via Corticotropin Releasing Hormone, Neurotensin, and Substance P: A Link to Neurogenic Skin Disorders", <i>Brain Behavior, and Immunity</i> , Vol. 13, pp. 225-239, 1999.
	AFFFFFFFFFF	Smith, and Barker, "Cell Trafficking and Role of Adhesion Molecules in Psoriasis", <i>Clinics in Dermatology</i> , Vol. 13, pp. 151-160, 1995.
	AGGGGGGGGGG	Somerville, and Scott, "Neoral-New Cyclosporin For Old?", <i>British Journal of Rheumatology</i> , Vol. 36, pp. 1113-1115, 1997.
	AHHHHHHHHHH	Spuls, et al., "A Systematic Review of Five Systematic Treatments for Severe Psoriasis", <i>British Journal of Dermatology</i> , Vol. 137, pp. 943-949, 1997.
	AIIIIIIIII	Storkus, and Dawson, "A Target Structures Involved in Natural Killing (NK): Characteristics, Distribution, and Candidate Molecules", <i>Immunology</i> , Vol. 10, No. 5, 393-416, 1991.
	AJJJJJJJJJ	Stern, "Utilization of Outpatient Care for Psoriasis", <i>Journal of the American Academy of Dermatology</i> , Vol. 35, no. 4, pp. 543-549, 1996.
	AKKKKKKKKKK	Stern, "Narrowband UV-B and Psoriasis", <i>Arch Dermatol</i> , Vol. 133, pp. 1587-1588, 1997.
	ALLLLLLLLLL	Stern, "Psoriasis", <i>The Lancet</i> , Vol. 350, pp. 349-353, 1997.
	AMMMMMMMMMMM	Stern, et al., "Malignant Melanoma in Patients Treated for Psoriasis with Methoxsalen (Psoralen) and Ultraviolet A Radiation (PUVA)", <i>The New England Journal of Medicine</i> , Vol. 336, No. 15, pp. 1041-1045, 1997.
	ANNNNNNNNNN	Stern, et al., "The Safety of Etretinate as Long-Term Therapy for Psoriasis: Results of the Etretinate Follow-Up Study", <i>Journal of the American Academy of Dermatology</i> , Vol. 33, No. 1, pp. 44-52, 1995.
	AOOOOOOOOOO	Sultan, et al., "Blockade of CD2-LFA-3 Interactions Protects Human Skin Allografts in Immunodeficient Mouse/Human Chimeras", <i>Nature Biotechnology</i> , Vol. 15, pp. 759-762, 1997.
	APPPPPPPPPP	Sutherland, et al., "Standards for Trials of Therapy in Inflammatory Bowel Disease", <i>Inflammatory Bowel Diseases</i> , Vol. 3, No. 4, pp. 277-283, 1997.
	AQQQQQQQQQQ	Talwar, et al., "Sequential Clinico-Histological Studies in Psoriasis Following Methotrexate Therapy", <i>Ind J Dermatol Venereol Leprol</i> , Vol. 61, pp. 284-287, 1995.
	ARRRRRRRRRR	Task Force of the Working Group on Arrhythmias of the European Society of Cardiology, "The Early Termination of Clinical Trials: Causes, Consequences, and Control", <i>European Heart Journal</i> , Vol. 15, pp. 721-738, 1994.
	ASSSSSSSSSS	Thomas, et al., "Transdermal Nicotine as Maintenance Therapy for Ulcerative Colitis", <i>The New England Journal of Medicine</i> , Vol. 332, No. 15, pp. 988-992, 1995.
	ATTTTTTTTTT	Traupe, "The Puzzling Genetics of Psoriasis", <i>Clinics in Dermatology</i> , Vol. 13, pp. 99-103, 1995.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Pre-filled)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR 1.98(b))		Applicant <b>Wallner et al.</b>	
		Filing Date December 5, 2000	Group Art Unit

### Other Documents (include Author, Title, Date, and Place of Publication)

Exam iner Initial	Desig. ID	Document
	AUUUUUUUUUU	Trembath, et al., "Identification of a Major Susceptibility Locus on Chromosome 6p and Evidence for Further Disease Loci Revealed by a Two Stage Genome-Wide Search in Psoriasis", <i>Human Molecular Genetics</i> , Vol. 6, No. 5, pp. 813-820, 1997.
	AVVVVVVVVVV	Urlaub, and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity", <i>Proc Natl Acad Sci</i> , Vol. 77, No. 7, pp. 4216-4220, 1980.
	AWWWWWWWWWW	Urlaub, et al., "Effect of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions", <i>Somatic Cell and Molecular Genetics</i> , Vol. 12, No. 6, pp. 555-566, 1986.
	AXXXXXXXXXXX	Valdimarsson, et al., "Psoriasis: A T-Cell-Mediated Autoimmune Disease Induced by Streptococcal Superantigens?", <i>Immunology Today</i> , Vol. 16, no. 3, pp. 145-149, 1995.
	AYYYYYYYYYY	Van de Kerkhof, "An Update on Vitamin D3 Analogues in the Treatment of Psoriasis", <i>Skin Pharmacology and Applied Skin Physiology</i> , Vol. 11, pp. 2-10, 1998.
	AZZZZZZZZZZ	Van de Kerkhof, "The Psoriasis Area and Severity Index and Alternative Approaches for the Assessment of Severity: Persisting Areas of Confusion", <i>British Journal of Dermatology</i> , Vol. 137, pp. 661-662, 1997.
	AAAAAAAAAAAAA	Van de Kerkhof, "Reduction of Epidermal Abnormalities and Inflammatory Changes in Psoriatic Plaques During Treatment with Vitamin D3 Analogs", <i>Journal of Investigative Dermatology Symposium Proceedings</i> , Vol. 1, pp. 78-81, 1996.
	ABBBBBBBBBBBB	Van de Kerkhof, "Review: The Management of Psoriasis", <i>Netherlands Journal of Medicine</i> , Vol. 52, pp. 40-45, 1998.
	ACCCCCCCCCCCC	Van de Kerkhof, et al., "The Effect of Addition of Calcipotriol Ointment (50 µg/g) to Acitretin Therapy in Psoriasis", <i>British Journal of Dermatology</i> , Vol. 138, pp. 84-89, 1998.
	ADDDDDDDDDDDD	Van de Kerkhof, et al., "Evaluation of Topical Drug Treatment in Psoriasis", <i>Dermatology</i> , Vol. 197, pp. 31-36, 1998.
	AEEEEEEEEEEEE	Van der Merwe, et al., "Human Cell-Adhesion Molecule CD2 Binds CD58 (LFA-3) with a Very Low Affinity and an Extremely Fast Dissociation Rate but does not Bind CD48 or CD59", <i>Biochemistry</i> , Vol. 33, pp. 10149-10160, 1994.
	AFEEEEEEEEEEE	Van der Rhee, et al., "Combined Treatment of Psoriasis with a New Aromatic Retinoid (Tigason) in Low Dosage Orally and Triamcinolone Acetonide Cream Topically: A Double-Blind Trial", <i>British Journal of Dermatology</i> , Vol. 102, pp. 203-211, 1980.
	AGGGGGGGGGGGG	Van Kooyk, et al., "Enhancement of LFA-1-Mediated Cell Adhesion by Triggering through CD2 or CD3 on T Lymphocytes", <i>Nature</i> , Vol. 342, pp. 811-813, 1989.
	AHHHHHHHHHHHH	Van Onselen, "Psoriasis in General Practice", <i>Nursing Standard</i> , Vol. 12, No. 30, pp. 32-33, 1998.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
10274-006002Application No.  
09/730,465**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant  
Wallner et al.Filing Date  
December 5, 2000

Group Art Unit

(37 CFR § 1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AAAAAAAAAAAA	Verstuyf, et al., "Recent Developments in the Use of Vitamin D Analogues", <i>Expert Opin Investig Drugs</i> , Vol. 9, No. 3, pp. 397-403, 1998.
	AJJJJJJJJJJ	Wahl, "The Impact of Psoriasis on Psychosocial Life Domains: A Review", <i>Scandinavian Journal of Caring Science</i> , Vol. 11, pp. 243-249, 1997.
	AKKKKKKKKKKK	Wahl, et al., "Sulfasalazine: A Potent and Specific Inhibitor of Nuclear Factor Kappa B", <i>Journal of Clinical Investigation</i> , Vol. 101, No. 5, pp. 1163-1174, 1998.
	ALLLLLLLLLLL	Wang, et al., "Structure of a Heterophilic Adhesion Complex between the Human CD2 and CD58 (LFA-3) Counterreceptors", <i>Cell</i> , Vol. 97, pp. 971-803, 1999.
	MMMMMMMMMMMM	Wanquing, et al., "Clinical Study of Cyclosporin A for Psoriasis in China", <i>Annals of Dermatology</i> , Vol. 7, No. 4, pp. 313-317, 1995.
	NNNNNNNNNNNN	Weinblatt, et al., "Methotrexate for Chronic Diseases in Adults", <i>The New England Journal of Medicine</i> , Vol. 332, No. 5, pp. 330-331, 1995.
	AOOOOOOOOOOO	Weiner, et al., "Phase I Evaluation of an Anti-Breast Carcinoma Monoclonal Antibody 260F9-Recombinant Ricin A Chain Immunoconjugate", <i>Cancer Research</i> , Vol. 49, pp. 4062-4067, 1989.
	APPPPPPPPPPP	Weinstein, "Psoriasis Therapy After Remission: The Next Step", <i>International Journal of Dermatology</i> , Vol. 36, pp. 37-40, 1997.
	AQQQQQQQQQQQ	Weinstein, "Tazarotene Gel: Efficacy and Safety in Plaque Psoriasis", <i>Journal of the American Academy of Dermatology</i> , Vol. 37, No. 2, pp. S33-S38, 1997.
	ARRRRRRRRRRR	Weinstein, et al., "Tazarotene Gel, a New Retinoid, for Topical Therapy of Psoriasis: Vehicle-Controlled Study of Safety, Efficacy, and Duration of Therapeutic Effect", <i>Journal of the American Academy of Dermatology</i> , Vol. 37, No. 1, pp. 85-92, 1997.
	ASSSSSSSSSSS	Weiss, and Ashwell, "The Asialoglycoprotein Receptor: Properties and Modulation by Ligand", BAUMANN, P., ET AL. (ED.). PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH, VOL. 300
	ATTTTTTTTTTT	Whitmore, and Morison, "Melanoma after PUVA Therapy for Psoriasis", <i>The New England Journal of Medicine</i> , Vol. 337, No. 7, pp. 502, 1997.
	AUUUUUUUUUUU	Wilkens, et al., "Randomized, Double-Blind, Placebo Controlled Trial of Low-Dose Pulse Methotrexate in Psoriatic Arthritis", <i>Arthritis and Rheumatism</i> , Vol. 27, No. 4, pp. 376-381, 1984.
	AVVVVVVVVVVV	Wolska, et al., "Etrretinate in Severe Psoriasis: Results of Double-Blind Study and Maintenance Therapy in Pustular Psoriasis", <i>Journal of the American Academy of Dermatology</i> , Vol. 9, No. 6, pp. 883-887, 1983.
	WWWWWWWWW	Wright, et al., "Human Low-Dosage Parenteral Methotrexate Therapy: A Controlled Toxicity Study", <i>Arch Derm</i> , Vol. 93, pp. 731-736, 1966.
	AXXXXXXXXXXXX	Yocum, et al., "Clinical and immunological effects of a Primatized Anti-CD4 Monoclonal Antibody in Active Rheumatoid Arthritis: Results of a Phase I, Single Dose, Dose Escalating Trial", <i>Journal of Rheumatology</i> , Vol. 25, pp. 1257-1262, 1998.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Rev. 2007)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-006002	Application No. 09/730,465
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR § 9.98(b))		Applicant Wallner et al.	
		Filing Date December 5, 2000	Group Art Unit

**Other Documents (include Author, Title, Date, and Place of Publication)**

Exam iner Initial	Desig. ID	Document
	YYYYYYYYYYYY	Young, et al., "A Prospective study of Renal Structure and Function in Psoriasis Patients with Cyclosporin", <i>Kidney International</i> , Vol. 46, pp. 1216-1222, 1994.
	ZZZZZZZZZZ	Zachariae, "Alcohol Interactions with Drugs and its Effects on the Treatment of Skin Diseases", <i>Clinics in Dermatology</i> , Vol. 17, pp. 443-445, 1999.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	